Assessment of Patient-Reported Naloxone Acquisition and Carrying With an Automated Text Messaging System After Emergency Department Discharge in Philadelphia.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 03 2022
01 03 2022
Historique:
entrez:
24
3
2022
pubmed:
25
3
2022
medline:
15
4
2022
Statut:
epublish
Résumé
A central tenet of harm reduction and prevention of opioid overdose deaths is the distribution and use of naloxone. Patient-centered methods that investigate naloxone acquisition and carrying can guide opioid overdose education and naloxone distribution efforts. To assess patients' self-reported naloxone acquisition and carrying after an emergency department (ED) encounter using automated text messaging. This cohort study investigated self-reported patient behaviors involving naloxone after ED discharge in a large, urban academic health system in Philadelphia, Pennsylvania. Adult patients who were prescribed or dispensed naloxone and who had a mobile phone number listed in the electronic health record provided informed consent after ED discharge, and data were collected prospectively using text messaging from October 10, 2020, to March 19, 2021. Patients who did not respond to the survey or who opted out were excluded. Automated text message-based survey after ED discharge for patients who were prescribed or dispensed naloxone. The primary outcome was patient-reported naloxone acquisition, carrying, and use. Descriptive statistics were used to summarize patient demographic characteristics. Of 205 eligible patients, 41 (20.0%) completed the survey; of those patients, the mean (SD) age was 39.5 (13.7) years, and 21 (51.2%) were women. Fifteen (36.6%) had a personal history of being given naloxone after an overdose. As indicated by the ED record, 27 participants (65.9%) had naloxone dispensed in the ED, and 36 (87.8%) self-reported acquiring naloxone during or after their ED visit. Twenty-four participants (58.5%) were not carrying naloxone in the week before their ED visit. Twenty participants (48.8%) were carrying naloxone after the ED visit, and 27 (65.9%) reported planning to continue carrying naloxone in the future. Of the 24 individuals (58.5%) not carrying naloxone before their ED encounter, 13 (54.2%) reported planning to continue carrying naloxone in the future. In this cohort study of adult patients dispensed or prescribed naloxone from the ED, most reported acquiring naloxone on or after discharge. The ED remains a key point of access to naloxone for individuals at high risk of opioid use and overdose, and text messaging could be a method to engage and motivate patient-reported behaviors in enhancing naloxone acquisition and carrying.
Identifiants
pubmed: 35323949
pii: 2790438
doi: 10.1001/jamanetworkopen.2022.3986
pmc: PMC8948533
doi:
Substances chimiques
Analgesics, Opioid
0
Naloxone
36B82AMQ7N
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e223986Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR000003
Pays : United States
Références
J Emerg Med. 2012 Mar;42(3):317-21
pubmed: 20828975
Ann Emerg Med. 2021 Sep;78(3):434-442
pubmed: 34172303
West J Emerg Med. 2018 Nov;19(6):1036-1042
pubmed: 30429939
Addict Sci Clin Pract. 2017 Jan 7;12(1):4
pubmed: 28061909
Am J Emerg Med. 2021 Sep;47:154-157
pubmed: 33812332
Subst Abus. 2021;42(4):646-653
pubmed: 32881639
J Subst Abuse Treat. 2019 May;100:39-44
pubmed: 30898326
Ann Intern Med. 2007 Oct 16;147(8):573-7
pubmed: 17938396
Acad Emerg Med. 2008 Sep;15(9):825-31
pubmed: 19244633
J Patient Exp. 2021 Oct 7;8:23743735211048057
pubmed: 34660887
Acad Emerg Med. 2012 Aug;19(8):949-58
pubmed: 22849787
LDI Issue Brief. 2012 Jul-Aug;17(9):1-4
pubmed: 22934330
N Engl J Med. 2012 Jul 5;367(1):1-3
pubmed: 22716935
Int J Drug Policy. 2017 Aug;46:172-179
pubmed: 28687187
Am J Emerg Med. 2019 Jan;37(1):164-165
pubmed: 29804791
Psychiatry Res. 2016 Sep 30;243:255-62
pubmed: 27423123
JMIR Mhealth Uhealth. 2020 Aug 4;8(8):e17281
pubmed: 32749997